CDK9-IN-7

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CDK9-IN-7 (compound 21e) 是一种高效选择性的，具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM)，与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡，在 G2 期阻滞细胞周期，并具有抑制非小细胞肺癌干细胞特性。

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC.

CDK9-IN-7 displays exceptional potency against NSCLC cell lines, especial A549 and H1299 with IC50 values less than 0.5 μM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency with an IC50 value of 0.837 μM.

——

——

Cell Cycle/DNA Damage

CDK

CDK

——

——

2369981-71-3

547.71

C29H37N7O2S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 62.5 mg/mL (114.11 mM; 超声助溶 )

C(N(C)C)(=O)C=1N(C=2C(C1)=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N2)C4CCCC4

——

(-20℃)

With Ice Pack

≥ 2 years